Hyper Hep B Indications/Uses

Recommendations on post-exposure prophylaxis are based on available efficacy data and on the likelihood of future HBV exposure for the person requiring treatment. In all exposures, a regimen combining hepatitis B immune globulin (human) with hepatitis B vaccine will provide both short- and long-term protection, will be less costly than the 2-dose hepatitis B immune globulin (human) treatment alone, and is the treatment of choice.
Post-exposure prophylaxis in the following situations:
Acute Exposure to Blood Containing HBsAg: After either parenteral exposure eg, by accidental 'needlestick' or direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident) involving HBsAg-positive materials eg, blood, plasma or serum. For inadvertent percutaneous exposure, a regimen of 2 doses of hepatitis B immune globulin (human), one given after exposure and one a month later, is about 75% effective in preventing hepatitis B in this setting.
Perinatal Exposure of Infants Born to HBsAg-Positive Mothers: Infants born to HBsAg-positive mothers are at risk of being infected with hepatitis B virus and becoming chronic carriers. This risk is especially great if the mother is HBeAg-positive. For an infant with perinatal exposure to an HBsAg- and HBeAg-positive mother, a regimen combining 1 dose of hepatitis B immune globulin (human) at birth with the hepatitis B vaccine series started soon after birth is 85-95% effective in preventing development of the HBV carrier state. Regimens involving either multiple doses of hepatitis B immune globulin (human) alone or the vaccine series alone have 70-90% efficacy, while a single dose of hepatitis B immune globulin (human) alone has only 50% efficacy.
Sexual Exposure to an HBsAg-Positive Person: Sex partners of HBsAg-positive persons are at increased risk of acquiring HBV infection. For sexual exposure to a person with acute hepatitis B, a single dose of hepatitis B immune globulin (human) is 75% effective if administered within 2 weeks of last sexual exposure.
Household Exposure to Persons with Acute HBV Infection: Since infants have close contact with primary caregivers and they have a higher risk of becoming HBV carriers after acute HBV infection, prophylaxis of an infant <12 months with hepatitis B immune globulin and hepatitis B vaccine is indicated if the mother or primary caregiver has acute HBV infection.
Administration of hepatitis B immune globulin (human) either preceding or concomitant with the commencement of active immunization with hepatitis B vaccine provides for more rapid achievement of protective levels of hepatitis B antibody, than when the vaccine alone is administered. Rapid achievement of protective levels of antibody to hepatitis B virus may be desirable in certain clinical situations, as in cases of accidental inoculations with contaminated medical instruments.
Administration of hepatitis B immune globulin (human) either 1 month preceding or at the time of commencement of a program of active vaccination with hepatitis B vaccine has been shown not to interfere with the active immune response to the vaccine.